Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells.

PubWeight™: 1.12‹?› | Rank: Top 10%

🔗 View Article (PMC 3001013)

Published in J Biol Chem on October 18, 2010

Authors

Efstratios Katsoulidis1, Evangelos Mavrommatis, Jennifer Woodard, Mario A Shields, Antonella Sassano, Nathalie Carayol, Konrad T Sawicki, Hidayatullah G Munshi, Leonidas C Platanias

Author Affiliations

1: Robert H Lurie Comprehensive Cancer Center and Division of Hematology Oncology, Northwestern University Medical School and Jesse Brown Veteran Affairs Medical Center, Chicago, Illinois 60611, USA.

Articles citing this

SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Clin Cancer Res (2015) 1.52

Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells. Mol Cell Biol (2015) 1.42

Interferons and their stimulated genes in the tumor microenvironment. Semin Oncol (2014) 1.07

The schlafen family of proteins and their regulation by interferons. J Interferon Cytokine Res (2013) 0.99

Regulatory effects of programmed cell death 4 (PDCD4) protein in interferon (IFN)-stimulated gene expression and generation of type I IFN responses. Mol Cell Biol (2012) 0.90

Schlafen 3 changes during rat intestinal maturation. Am J Surg (2012) 0.89

SLFN11 inhibits checkpoint maintenance and homologous recombination repair. EMBO Rep (2015) 0.87

Regulation of epithelial differentiation in rat intestine by intraluminal delivery of an adenoviral vector or silencing RNA coding for Schlafen 3. PLoS One (2013) 0.85

The correlation between the expression of differentiation markers in rat small intestinal mucosa and the transcript levels of schlafen 3. JAMA Surg (2013) 0.83

Expression and regulatory effects of murine Schlafen (Slfn) genes in malignant melanoma and renal cell carcinoma. J Biol Chem (2013) 0.83

Regulation of interferon-dependent mRNA translation of target genes. J Interferon Cytokine Res (2014) 0.82

Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis. Int J Cancer (2013) 0.82

Characterization of Novel Ribosome-Associated Endoribonuclease SLFN14 from Rabbit Reticulocytes. Biochemistry (2015) 0.81

Expression and regulation of Schlafen (SLFN) family members in primary human monocytes, monocyte-derived dendritic cells and T cells. Results Immunol (2015) 0.80

High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment. BMC Cancer (2015) 0.79

Schlafen 4-expressing myeloid-derived suppressor cells are induced during murine gastric metaplasia. J Clin Invest (2016) 0.79

Schlafen 12 expression modulates prostate cancer cell differentiation. J Surg Res (2014) 0.79

SCHLAFEN 5 expression correlates with intestinal metaplasia that progresses to gastric cancer. J Gastroenterol (2016) 0.77

The soluble cytoplasmic tail of CD45 (ct-CD45) in human plasma contributes to keep T cells in a quiescent state. Eur J Immunol (2016) 0.75

Articles cited by this

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (1994) 26.02

How cells respond to interferons. Annu Rev Biochem (1998) 24.27

Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 11.57

Primary bioassay of human tumor stem cells. Science (1977) 9.69

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Melanoma. N Engl J Med (2006) 8.80

Interferons and their actions. Annu Rev Biochem (1987) 8.36

Viruses and interferon: a fight for supremacy. Nat Rev Immunol (2002) 7.92

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60

Complex modulation of cell type-specific signaling in response to type I interferons. Immunity (2006) 4.48

High-frequency mutagenesis of human cells and characterization of a mutant unresponsive to both alpha and gamma interferons. Proc Natl Acad Sci U S A (1991) 3.83

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol (2003) 3.13

Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins. Science (1995) 3.10

Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med (2004) 2.59

Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev (2003) 2.24

High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem (2003) 2.24

Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci U S A (2003) 2.07

Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci U S A (2004) 2.04

Schlafen, a new family of growth regulatory genes that affect thymocyte development. Immunity (1998) 2.04

Mesenchymal cells reactivate Snail1 expression to drive three-dimensional invasion programs. J Cell Biol (2009) 1.99

Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem (1999) 1.94

Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci U S A (2008) 1.81

Modulation of T cell development and activation by novel members of the Schlafen (slfn) gene family harbouring an RNA helicase-like motif. Int Immunol (2004) 1.76

Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem (1997) 1.76

Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem (2002) 1.72

Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem (2001) 1.71

Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer (2009) 1.69

Interferons: mechanisms of action and clinical applications. Curr Opin Oncol (2003) 1.56

Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. J Biol Chem (2004) 1.50

Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem (2004) 1.48

The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem (2000) 1.47

Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem (2006) 1.41

An Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence. Nat Immunol (2010) 1.39

Schlafen-1 causes a cell cycle arrest by inhibiting induction of cyclin D1. J Biol Chem (2005) 1.37

Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem (2003) 1.36

The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem (2001) 1.33

Novel transcriptional regulation of the schlafen-2 gene in macrophages in response to TLR-triggered stimulation. Mol Immunol (2007) 1.32

Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res (2006) 1.31

Activation of protein kinase C delta by IFN-gamma. J Immunol (2003) 1.25

Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res (2004) 1.25

Evolution of the Schlafen genes, a gene family associated with embryonic lethality, meiotic drive, immune processes and orthopoxvirus virulence. Gene (2009) 1.24

Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J Biol Chem (2004) 1.24

The p38 mitogen-activated protein kinase pathway in interferon signal transduction. J Interferon Cytokine Res (2005) 1.23

Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci U S A (2009) 1.17

Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells. Clin Cancer Res (2007) 1.16

Role of Schlafen 2 (SLFN2) in the generation of interferon alpha-induced growth inhibitory responses. J Biol Chem (2009) 1.14

Subcellular localization of the Schlafen protein family. Biochem Biophys Res Commun (2008) 1.13

Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide. J Biol Chem (2006) 1.11

Engagement of protein kinase C-theta in interferon signaling in T-cells. J Biol Chem (2004) 1.10

Schlafen-3: a novel regulator of intestinal differentiation. Biochem Biophys Res Commun (2009) 1.08

Activation of the phosphatidylinositol 3-kinase serine kinase by IFN-alpha. J Immunol (1997) 1.06

The Hsp40 family chaperone protein DnaJB6 enhances Schlafen1 nuclear localization which is critical for promotion of cell-cycle arrest in T-cells. Biochem J (2008) 1.00

The paternal gene of the DDK syndrome maps to the Schlafen gene cluster on mouse chromosome 11. Genetics (2005) 0.99

Histone deacetylase inhibitors suppress IFNalpha-induced up-regulation of promyelocytic leukemia protein. Blood (2006) 0.97

Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells. Exp Hematol (2005) 0.94

Activation of protein kinase C{eta} by type I interferons. J Biol Chem (2009) 0.88

High density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional response in melanoma cells. Br J Cancer (2001) 0.87

Resistance of melanoma cell lines to interferons correlates with reduction of IFN-induced tyrosine phosphorylation. Induction of the anti-viral state by IFN is prevented by tyrosine kinase inhibitors. J Immunol (1995) 0.84

Quieting T cells with Slfn2. Nat Immunol (2010) 0.81

Articles by these authors

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

Actin is part of pre-initiation complexes and is necessary for transcription by RNA polymerase II. Nat Cell Biol (2004) 3.43

TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst (2014) 2.08

Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy. Oncology (Williston Park) (2010) 2.07

Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol Cell Biol (2005) 1.97

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood (2008) 1.95

Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci U S A (2008) 1.81

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A (2010) 1.75

Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem (2002) 1.72

Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem (2001) 1.71

AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol Ther (2010) 1.66

Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood (2012) 1.66

ATP-mediated Erk1/2 activation stimulates bacterial capture by filopodia, which precedes Shigella invasion of epithelial cells. Cell Host Microbe (2011) 1.63

Interferons: mechanisms of action and clinical applications. Curr Opin Oncol (2003) 1.56

Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma (2009) 1.53

Jak family of kinases in cancer. Cancer Metastasis Rev (2003) 1.52

Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis. J Biol Chem (2004) 1.49

Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer (2008) 1.48

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood (2006) 1.48

MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma. Proc Natl Acad Sci U S A (2002) 1.47

Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res (2010) 1.46

Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol (2002) 1.41

Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem (2006) 1.41

Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res (2005) 1.40

Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res (2010) 1.38

Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem (2003) 1.36

Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J Biol Chem (2011) 1.35

Statins in tumor suppression. Cancer Lett (2008) 1.34

Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochem J (2012) 1.33

Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene (2002) 1.32

Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res (2011) 1.31

Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res (2006) 1.31

Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res (2011) 1.29

The interferon consensus sequence-binding protein activates transcription of the gene encoding neurofibromin 1. J Biol Chem (2004) 1.29

Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther (2008) 1.28

Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1. Cancer Res (2006) 1.27

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood (2013) 1.26

Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget (2011) 1.26

Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res (2004) 1.25

Activation of protein kinase C delta by IFN-gamma. J Immunol (2003) 1.25

The p38 mitogen-activated protein kinase pathway in interferon signal transduction. J Interferon Cytokine Res (2005) 1.23

Role of p38alpha Map kinase in Type I interferon signaling. J Biol Chem (2003) 1.23

Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. J Immunol (2008) 1.22

Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J Biol Chem (2008) 1.21

Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)- and ribosomal protein S6K-mediated signals. Mol Cell Biol (2009) 1.21

Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res (2007) 1.20

Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum (2004) 1.19

Transforming growth factor-beta 1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression. Mol Cancer Res (2008) 1.19

Slug is a downstream mediator of transforming growth factor-beta1-induced matrix metalloproteinase-9 expression and invasion of oral cancer cells. J Cell Biochem (2009) 1.18

Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J Biol Chem (2010) 1.17

Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One (2012) 1.17

Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci U S A (2009) 1.17

Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem (2002) 1.17

The PI3' kinase pathway in interferon signaling. J Interferon Cytokine Res (2005) 1.17

Role of Schlafen 2 (SLFN2) in the generation of interferon alpha-induced growth inhibitory responses. J Biol Chem (2009) 1.14

Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase. J Biol Chem (2003) 1.14

Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proc Natl Acad Sci U S A (2003) 1.14

Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res (2008) 1.13

Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. Blood (2013) 1.13

Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res (2005) 1.13

Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice. Cancer Res (2011) 1.13

Interplay between β1-integrin and Rho signaling regulates differential scattering and motility of pancreatic cancer cells by snail and Slug proteins. J Biol Chem (2012) 1.12

AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. Biochem Biophys Res Commun (2010) 1.12

Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma (2008) 1.11

Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide. J Biol Chem (2006) 1.11

Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. J Biol Chem (2007) 1.11

Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res (2009) 1.10

Engagement of protein kinase C-theta in interferon signaling in T-cells. J Biol Chem (2004) 1.10

Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res (2010) 1.10

Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther (2006) 1.09